Myeloma Patient Articles & Analysis: Older
5 news found
A startup team from the University of Wisconsin that moved to San Diego in January to advance their technology for optimizing treatment regimens for cancer patients won the audience vote for best pitch at the EvoNexus Spring Demo Day last week. Lynx Biosciences founder and CEO Chorom Pak said her startup has developed microfluidic technology that uses live cancer ...
Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs) with Menarini Silicon Biosystems’ CELLSEARCH® System and the CELLSERCH® Circulating Multiple Myeloma Cell (CMMC) Test* can be used to monitor and manage patients with Multiple Myeloma (MM) even at asymptomatic precursor stages ...
The delivery system and program have proven viability and we believe we are well situated to advance to Phase 1b/2 in multiple myeloma patients.” The Company previously announced that the upcoming Phase 1b/2 clinical study in multiple myeloma is on track to begin enrollment in Q4 2022 at three already identified sites in the European ...
I look forward to continuing to advance this program to the multiple myeloma patient popluations with a need for enhanced tolerability,” said Mohamad Hussein, Scientific Committee Chair. The company also announced that the upcoming Phase 1b/2 clinical study in multiple myeloma is on track to begin enrollment in Q4 2022 at three already ...
Despite advances in treatment, multiple myeloma remains an incurable disease, and many patients suffer through periods of remission and relapse. ...